Columbia Laboratories has raised $4.7 million in gross proceeds to the company through the sale of approximately 1.3 million shares of its common stock at a price of $3.50 per share in a registered direct offering.
Subscribe to our email newsletter
Net proceeds are expected to be approximately $4.1 million after offering-related fees and expenses.
Columbia intends to use the net proceeds from the offering for general corporate purposes, including funding its clinical development and other R&D activities, internal and collaborative sales, marketing and distribution expenditures, capital expenditures and working capital needs.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.